Inovio Pharmaceuticals, Inc. ( INO) Stock. Should you Buy or Sell? $ 2.22
0.06 (2.63 %)
Inovio Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | INO |
| Price | $2.22 |
| Beta | 0.879 |
| Volume Avg. | $6.28 M |
| Market Cap | $553.67 M |
| 52 Week Range | $1.38 - $8.15 |
Inovio Pharmaceuticals, Inc. opened the day at $2.22 which is +'2.63 % on yesterday's close. Inovio Pharmaceuticals, Inc. has a 52 week high of $8.15 and 52 week low of $1.38, which is a difference of $6.77. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $553.67 M and total net profit is $1774758 which means the company is trading at 311.97 times profit to market capitalization. Theoretically, if you were to buy Inovio Pharmaceuticals, Inc. for $553.67 M, it would take 15 years to get your money back. Inovio Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Inovio Pharmaceuticals, Inc. Stock Forecast - Is Inovio Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -1.480 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -204.859 |
Valuing Inovio Pharmaceuticals, Inc.
| Price Book Value Ratio | 1.369 | Price To Book Ratio | 1.369 |
| Price To Sales Ratio | 303.266 | Price Earnings Ratio | -1.480 |
How liquid is Inovio Pharmaceuticals, Inc.
| Current Ratio | 6.737 |
| Quick Ratio | 6.198 |
Debt
| Debt Ratio | 0.203 | Debt Equity Ratio | 0.255 |
| Long Term Debt To Capitalization | 0.080 | Total Debt To Capitalization | 0.087 |
Latest news about Inovio Pharmaceuticals, Inc.
Its newly announced cost-saving measures are getting a warm reception.
Inovio (INO) delivered earnings and revenue surprises of -53.33% and 264.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Thomas Hong - IR Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer David Liebowitz - SVP, Clinical Development Jeffrey Skolnik - SVP, Clinical Development Peter Kies - CFO Conference Call Participants Alexandria Hammond - Bank of America Merrill Lynch Gregory Renza - RBC Capital Markets Jiale Song - Jefferies Eka Gigauri - Oppenheimer Raghuram Selvaraju - H.C. Wainwright & Co. Yi Chen - H.C.
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
The last few years haven't been kind to Inovio Pharmaceuticals.
About Inovio Pharmaceuticals, Inc.
Description :
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
